Comparative Pharmacology
Head-to-head clinical analysis: CARTROL versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTROL versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
CARTROL vs PROPRANOLOL HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and reduces CNS sympathetic outflow.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
Initial: 40 mg orally twice daily; maintenance: 120-240 mg/day in 2-3 divided doses. Maximum: 640 mg/day. For hypertension, start 40 mg twice daily, increase gradually.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 3–6 hours, but clinical effects (e.g., beta-blockade) persist longer due to prolonged receptor occupancy. Half-life may increase in hepatic impairment.
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Primarily hepatic metabolism (>99%) with <1% excreted unchanged in urine. Metabolites are excreted renally. Fecal elimination is minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker